Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for AGL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 4.631M
March 31, 2026 -3.535M
December 31, 2025 -0.017M
September 30, 2025 -0.236M
June 30, 2025 -2.58M
March 31, 2025 -0.161M
December 31, 2024 -0.022M
September 30, 2024 -1.406M
June 30, 2024 -1.714M
March 31, 2024 0.559M
December 31, 2023 -0.845M
September 30, 2023 1.41M
June 30, 2023 -202.04M
Date Value
March 31, 2023 8.339M
December 31, 2022 1.13M
September 30, 2022 9.111M
June 30, 2022 4.309M
March 31, 2022 13.51M
December 31, 2021 10.42M
September 30, 2021 0.896M
June 30, 2021 1.113B
March 31, 2021 30.30M
December 31, 2020 -0.76M
September 30, 2020 -6.141M
June 30, 2020 4.154M
March 31, 2020 27.37M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Astrana Health, Inc. -104.07M
Starling Oncology, Inc. -0.218M
Nakamoto, Inc. -9.205M
American Oncology Network, Inc. --
Tenet Healthcare Corp. -1.179B